rAAV4

rAAV4 (recombinant adeno-associated virus 4) is a gene therapy vector belonging to Clade G. It is distinguished by its use of CD164, a type I transmembrane sialomucin, as an essential entry receptor, allowing it to transduce cells via a mechanism independent of the canonical AAV receptor (AAVR/KIAA0319L). In preclinical murine models, systemic administration of rAAV4 demonstrates a strong tropism for the lungs. The identification of CD164 as its primary receptor provides a molecular basis for engineering and optimizing Clade G AAV vectors for targeted in vivo gene delivery applications.

Other names

recombinant adeno-associated virus 4AAV4AAV-4AAV 4